Holen Sie sich die Stockscreener-App
8.94
5.55%
0.47
Handel nachbörslich:
9.01
0.07
+0.78%
Schlusskurs vom Vortag:
$8.47
Offen:
$8.72
24-Stunden-Volumen:
2.39M
Relative Volume:
1.23
Marktkapitalisierung:
$936.21M
Einnahmen:
$69.65M
Nettoeinkommen (Verlust:
$-81.27M
KGV:
-9.8371
EPS:
-0.9088
Netto-Cashflow:
$-79.45M
1W Leistung:
+26.99%
1M Leistung:
+46.56%
6M Leistung:
-16.60%
1J Leistung:
+87.03%
1-Tages-Spanne:
$8.60
$9.22
1-Wochen-Bereich:
$7.20
$9.22
52-Wochen-Spanne:
$3.84
$11.50
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.94 | 886.99M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
448.18 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.81 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.21 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.64 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.08 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - BioSpace
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - Moomoo
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Medicare Expands Coverage for Personalis NeXT Personal Test - TipRanks
US agency broadens coverage of Personalis breast cancer test - MSN
Expanded Medicare covers Personalis (NASDAQ: PSNL) NeXT Personal cancer test - Stock Titan
Personalis gains expanded Medicare coverage for breast cancer test By Investing.com - Investing.com Nigeria
US Agency Broadens Coverage Of Personalis Breast Cancer Test - Benzinga
Personalis Shares Rise After NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - marketscreener.com
Personalis (PSNL) Shares Climb on Expanded Medicare Coverage for NeXT Personal Test - GuruFocus
Personalis (PSNL) Expands Medicare Coverage for NeXT Personal Te - GuruFocus
Personalis gets expanded Medicare coverage for NeXT Personal - Seeking Alpha
Personalis secures fourth Medicare coverage decision for Next Personal, expanding breast cancer coverage to pre-surgical treatment monitoring - marketscreener.com
Personalis gains expanded Medicare coverage for breast cancer test - Investing.com
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
PSNL Stock Price, Quote & Chart | PERSONALIS INC (NASDAQ:PSNL) - ChartMill
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Personalis Secure Medicare Coverage For NeXT Personal MRD Test In Immunotherapy Monitoring; Stock Up - RTTNews
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis gains expanded Medicare coverage for cancer test - Investing.com UK
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com South Africa
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tempus AI, Inc. | 10% Owner |
Nov 25 '25 |
Buy |
10.62 |
23,600 |
250,665 |
12,918,346 |
| Tempus AI, Inc. | 10% Owner |
Dec 22 '25 |
Buy |
8.93 |
28,000 |
250,040 |
13,039,067 |
| Tempus AI, Inc. | 10% Owner |
Nov 21 '25 |
Buy |
9.40 |
26,499 |
249,190 |
12,869,521 |
| Tempus AI, Inc. | 10% Owner |
Nov 24 '25 |
Buy |
9.87 |
25,225 |
248,971 |
12,894,746 |
| Tempus AI, Inc. | 10% Owner |
Nov 19 '25 |
Buy |
8.12 |
30,645 |
248,837 |
12,814,195 |
| Tempus AI, Inc. | 10% Owner |
Nov 20 '25 |
Buy |
8.63 |
28,827 |
248,777 |
12,843,022 |
| Tempus AI, Inc. | 10% Owner |
Dec 17 '25 |
Buy |
7.86 |
31,650 |
248,769 |
12,949,996 |
| Tempus AI, Inc. | 10% Owner |
Dec 19 '25 |
Buy |
8.39 |
29,641 |
248,688 |
13,011,067 |
| Tempus AI, Inc. | 10% Owner |
Dec 18 '25 |
Buy |
7.91 |
31,430 |
248,611 |
12,981,426 |
| Tachibana Aaron | CFO AND COO |
Jan 22 '26 |
Option Exercise |
9.16 |
1,201 |
11,001 |
165,659 |
1.19%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):